PEPperPRINT and MalVa announce a joint project with respect to malaria vaccine development. PEPperPRINT’s peptide microarrays will be used to characterize the humoral immune response to MalVa’s novel malaria vaccine antigens. The goal of this project is to disclose highly immunogenic epitopes that are optimal candidates for MalVa’s multicomponent malaria vaccine approach.
Dr. Kirsten Heiß, CEO of MalVa: “Due to PEPperPRINT’s large peptide microarrays for initial discovery screens and their flexibility to easily adapt the peptide content to the project needs, PEPperPRINT is the optimal partner for our malaria vaccine development.”
Dr. Volker Stadler, CEO of PEPperPRINT: “MalVa’s knowledge in malaria research and their collaborative access to patient samples allows us to fully exploit the great potential of our PEPperCHIP® Peptide Microarray platform. It’s a great opportunity to be part of developing a vaccine against one of the most devastating diseases with hundreds of thousandsdeaths each year.”
Download press release [pdf]
PEPperPRINT is a young and innovative biotech company based in Heidelberg, Germany. The company provides the new PEPperCHIP® Peptide Microarray platform for epitope mapping, immunological research, analysis of serum profiles and kinase signatures, biomarker discovery and peptide drug development. Due to PEPperPRINT’s proprietary peptide laser printing technology, the high-content PEPperCHIP® microarrays set a new standard in terms of peptide diversity, signal quality and content flexibility.
MalVa specializes in Malaria vaccine development employing novel not yet described malarial pre-erythrocytic antigens. These antigens are currently tested in immunological and vaccination studies. MalVa aims to develop it’s core product MalVaccine towards a phase II clinical trial. Collaborative development and licensing agreements with an experienced pharmaceutical company will bring the product to the market.
For further information please contact:
Dr. Kirsten Heiß
Fax: +49 (0)1803 62222916203